Clinical Trial Update: Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the PK similarity between FYB206 and pembrolizumab (Keytruda) in resected stage II/III melanoma; status is active not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• FYB206 (pembrolizumab biosimilar)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Formycon AG | Conditions: Melanoma, Stage II, Melanoma Stage III | Phase 1 | Status: ACTIVE_NOT_RECRUITING